Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 nov. 2025 05h00 HE | Source: 4TEEN4 Pharmaceuticals GmbH

4TEEN4 Extends Series C Financing Round to €55 Million, Supporting Expanded Clinical Development of Procizumab in Cardiogenic Shock

4TEEN4 extends series C financing to EUR 55M ($64M) to increase footprint of the Phase 2a study across Europe and to support planned expansion into US.
23 juil. 2025 05h50 HE | Source: 4TEEN4 Pharmaceuticals GmbH

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

The trial will evaluate safety, dosing, and efficacy in patients with cardiogenic shock Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has...
15 juil. 2025 05h00 HE | Source: 4TEEN4 Pharmaceuticals GmbH

4TEEN4 Announces Publication in European Journal of Heart Failure Demonstrating First-in-Human Shock Reversal Evidence for Procizumab in Three Compassionate Use Cases

Data from three terminally ill cardiogenic shock patients showcase potential of procizumab to safely reverse shock within 48 hours and provide promising first-in-human evidence on the translatability...